Skip to main content
. Author manuscript; available in PMC: 2019 Nov 1.
Published in final edited form as: Mol Cancer Ther. 2018 Aug 9;17(11):2297–2308. doi: 10.1158/1535-7163.MCT-17-1239

Figure 4: Dual inhibition of AXL and MERTK reduces downstream signaling through oncogenic pathways.

Figure 4:

(A, B)UM-SCC1 and MDAMB231 cells were treated with vehicle (DMSO), R428, UNC2025, or R428+UNC2025 for 24 hours. (C) H1299 cells were transfected with AXL siRNA (siAXL10 or siAXL12) or non-targeting siRNA (siNT) and cells were treated with vehicle or UNC2025 for one hour. Expression of the indicated proteins was assessed in cell lysates by immunoblot. α-Tubulin is shown as a loading control. The data shown are representative of 3 independent experiments.